Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| 1507 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| Cleidocranial Dysplasia | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81479 | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Next Generation Sequencing and Copy Number Variation Analysis | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Alternate Names | ||||||||||||||||||||||||||||||
| CCD | ||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
RUNX2 related disorders - Cleidocranial dysplasia (CCD; MIM 119600) is an autosomal dominant disorder caused by mutations in the runt-related transcription factor 2 gene (RUNX2, CBFA1). The RUNX2 product is involved in the differentiation of mesenchymal precursor cells towards osteoblasts. The phenotypic affects of mutations in RUNX2 are potentially protean in consequence. Findings may include moderate short stature, delayed fontanelle closure, parietal, frontal and occipital bossing, open fontanelle in adults, hypertelorism, a low nasal bridge, cleft palate and or a narrow high arched palate with midface hypoplasia or micrognathia. Deafness and various dental abnormalities may also occur. Skeletal findings may include osteosclerosis, increased bone fragility, calvarial thickening, small, hypoplastic or absent clavicles, short ribs, spondylolysis, spondylolisthesis, scoliosis, kyphosis, wide pubic symphysis with delayed mineralization, hypoplastic iliac wing, a broad femoral head with a short neck and coxa vara. The hands may display brachydactyly, a long second metacarpal, short middle phalanges of the second and fifth fingers and abnormal cone shaped phalangeal epiphyses. Syringomyelia has also been observed. Missense, nonsense, splice site, deletion and insertion mutations are the most common mutation types described in RUNX2. Chromosomal translocations and large deletions have been rarely reported. Metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly (MDMHB; MIM 156510) is an autosomal dominant disorder caused by an intragenic duplication of exons 3 to 5 of RUNX2. While cleidocranial dysplasia results from loss of function mutations in RUNX2, MBMHB appears to be due to a gain of function of RUNX2. MDMHB is characterized by metaphyseal flaring and thin diaphyseal cortices of the long bones, enlargement of the medial halves of the clavicles, maxillary hypoplasia, and dystrophic teeth. The hands may display brachydactyly with short fifth metacarpals and short middle phalanges of the second and fifth fingers. Other features include mild short stature, wide ischial and pubic bones, mild thickening of frontal and parietal skull bones, platyspondyly, multiple small vertebral fractures, and osteoporosis. |
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| RUNX2 | ||||||||||||||||||||||||||||||
| MIM | ||||||||||||||||||||||||||||||
| 119600 | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Skeletal Disorders | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.